Brainxell reports preclinical data on BXT-110 for Parkinson’s disease

Nov. 4, 2025

Brainxell Inc. has reported preclinical data demonstrating efficacy of BXT-110, an autologous induced pluripotent stem cell (iPSC)-derived neuronal therapy for Parkinson’s disease.

BioWorld Science Neurology/psychiatric Cell therapy

Today's news in brief

BioWorld

BioWorld briefs for Nov. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 10, 2025.

Illustration of women's reproductive organs

Biomarker panel of three serum microRNAs predicts cervical cancer prognosis

BioWorld Science

MicroRNAs (miRNAs) play key roles in cancer development by regulating genes involved in cell growth, differentiation, invasion, metastasis and angiogenesis....

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...